← All trials
NCT04975178
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 31, 2022
- Primary completion
- Jun 30, 2027
- Completion date
- Sep 30, 2029
- First posted
- Jul 23, 2021
- Last posted
- Jul 23, 2021
- Enrollment
- 6960
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Biofabri, S.LLead sponsor
- Institut PasteurCollaborator
- University of Kwa-Zulu NatalCollaborator
- TuBerculosis Vaccine InitiativeCollaborator
- University of ZaragozaCollaborator
- Stellenbosch UniversityCollaborator
- University of Cape TownCollaborator
- Wits Health Consortium (Pty) LtdCollaborator
- Biomedical Research Center EPLSCollaborator
- University of Cape TownOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.